menu search

IQAIF / IQ-AI sent 4% higher following recent successful pre-clinical studies

IQ-AI sent 4% higher following recent successful pre-clinical studies
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, enjoyed a boost on the London market this Tuesday, with shares being sent 4% higher. Investors were buoyed by positive outcomes of two recent pre-clinical studies pertaining to the inhibitory effects of oral gallium maltolate (GaM) on two types of pediatric brain tumours. Read More
Posted: Jun 27 2023, 05:55
Author Name: Proactive Investors
Views: 112339

IQAIF News  

IQ-AI higlights use of subsidiary's software in brain cancer study

By Proactive Investors
October 18, 2023

IQ-AI higlights use of subsidiary's software in brain cancer study

IQ-AI has highlighted a new study into a rare form of brain cancer that used subsidiary Imaging  Biometric's dynamic susceptibility contrast (DSC) ma more_horizontal

IQ-AI subsidairy secures second orphan drug designation

By Proactive Investors
October 9, 2023

IQ-AI subsidairy secures second orphan drug designation

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s subsidiary, Imaging Biometrics, has secured orphan drug designation from the US Food and Drug Administration for more_horizontal

IQ-AI hails the latest data on IB Neuro technology

By Proactive Investors
September 8, 2023

IQ-AI hails the latest data on IB Neuro technology

Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has confirmed the effectiveness of its IB Neuro technology for brain scan more_horizontal

IQ-AI to focus on the commercial potential of its software alongside phase I study

By Proactive Investors
August 17, 2023

IQ-AI to focus on the commercial potential of its software alongside phase I study

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it aims to convert a significant portion of the 45 sites currently assessing its IB imaging software into clien more_horizontal

IQ-AI subsidiary Imaging Biometric has bone metastases tech selected by Medical College of Wisconsin

By Proactive Investors
July 19, 2023

IQ-AI subsidiary Imaging Biometric has bone metastases tech selected by Medical College of Wisconsin

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s wholly owned subsidiary Imaging Biometrics has had its handheld application IB Nimble selected by the Orthopedic D more_horizontal

IQ AI shares surge following promising subsidiary announcement

By Proactive Investors
July 13, 2023

IQ AI shares surge following promising subsidiary announcement

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) surged in early-Thursday trades following a promising update from its subsidiary Imaging Biometrics. Imaging Biometr more_horizontal

IQ-AI subsidiary wins orphan drug status for pediatric brain tumour treatment

By Proactive Investors
July 13, 2023

IQ-AI subsidiary wins orphan drug status for pediatric brain tumour treatment

Imaging Biometrics, a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), been has granted orphan drug designation (ODD) status for its oral more_horizontal

IQ-AI sent 4% higher following recent successful pre-clinical studies

By Proactive Investors
June 27, 2023

IQ-AI sent 4% higher following recent successful pre-clinical studies

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, enjoyed a boost on the Lond more_horizontal


Search within

Pages Search Results: